Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center

被引:86
作者
Zeller, T. [1 ]
Muenstedt, K. [2 ]
Stoll, C. [3 ]
Schweder, J. [4 ]
Senf, B. [4 ]
Ruckhaeberle, E. [5 ]
Becker, S. [6 ]
Serve, H. [7 ]
Huebner, J. [1 ]
机构
[1] Goethe Univ Frankfurt, Dr Senckenberg Chronomed Inst, D-60590 Frankfurt, Germany
[2] Univ Clin Giessen, Dept Gynecol & Obstet, D-35392 Giessen, Germany
[3] Klin Herzoghohe, D-95445 Bayreuth, Germany
[4] Goethe Univ Frankfurt, Dept Psychooncol, D-60590 Frankfurt, Germany
[5] Clin Gynecol & Obstet, D-04129 Leipzig, Germany
[6] Goethe Univ Frankfurt, Clin Gynecol & Obstet, D-60596 Frankfurt, Germany
[7] Goethe Univ Frankfurt, Med Clin 2, Dept Hematooncol, D-60590 Frankfurt, Germany
关键词
Complementary and alternative medicine; Breast cancer; Interactions of drugs; Chemotherapy; Endocrine therapy; Antibody therapy; CAM USE; WOMEN; DISCLOSURE; TRIALS;
D O I
10.1007/s00432-012-1336-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
About 40-50 % of cancer patients use complementary and alternative medicine (CAM). Women, and especially those with gynecological cancers, are more active in this field than men. The goal of our study was to estimate the likelihood of CAM use and the likelihood of interactions of CAM with cancer therapy in the setting of a gynecological outpatient clinic at a German Comprehensive Cancer Center (CCC). One hundred consecutive gynecological outdoor patients of the CCC in Frankfurt am Main in Germany were interviewed with a standardized questionnaire on CAM use. An investigation on potential interactions was done by matching a scientific database systematically. Sixty-nine of the interviewed 100 women received chemotherapy, 23 endocrine therapy and 41 monoclonal antibodies. In total, 64 % used CAM, 48 % used at least one substance-bound CAM. In 17 out of those 48 cases (35 %), interactions were unlikely, whereas they were probable in 14 patients (29 %). Thus, a third of all patients in this study were in danger of interactions. More than half of all CAM users and three quarters of users of substance-bound CAM are at risk of interactions. This number is independent of whether the patient is taking chemotherapy, endocrine therapy or antibodies. The frequency of CAM use we found is in line with international data from CCCs in the USA. To our knowledge, this is the first study publishing data on the frequency of potential interactions. Thus, an initiative to protect women from the dangers of uncontrolled CAM use is urgently needed. In the discussion, we propose a concept of how to achieve this aim.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 16 条
  • [1] Cassileth BR., 2003, HERB DRUG INTERACTIO
  • [2] Complementary and alternative medicine use by patients enrolled onto phase I clinical trials
    Dy, GK
    Bekele, L
    Hanson, LJ
    Furth, A
    Mandrekar, S
    Sloan, JA
    Adjei, AA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) : 4810 - 4815
  • [3] Lesson from comparison of CAM use by women with female-specific cancers to others: It's time to focus on interaction risks with CAM therapies
    Eschiti, Valerie S.
    [J]. INTEGRATIVE CANCER THERAPIES, 2007, 6 (04) : 313 - 344
  • [4] Henderson JW, 2004, ALTERN THER HEALTH M, V10, P52
  • [5] The relationship between cancer locus of control and complementary and alternative medicine use by women diagnosed with breast cancer
    Henderson, JW
    Donatelle, RJ
    [J]. PSYCHO-ONCOLOGY, 2003, 12 (01) : 59 - 67
  • [6] Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: A study of prognosis, quality of life, and preferences for decision making
    Hlubocky, Fay J.
    Ratain, Mark J.
    Wen, Ming
    Daugherty, Christopher K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 548 - 554
  • [7] Horneber M, 2011, INTEGR CANC THER
  • [8] Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology
    Micke, Oliver
    Bruns, Frank
    Glatzel, Michael
    Schoenekaes, Klaus
    Micke, Patrick
    Muecke, Ralph
    Buentzel, Jens
    [J]. EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2009, 1 (01) : 19 - 25
  • [9] Complementary and alternative medicine use in patients with gynecological cancers in Europe
    Molassiotis, A
    Browall, M
    Milovics, L
    Panteli, V
    Patiraki, E
    Fernandez-Ortega, P
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 219 - 224
  • [10] Complementary and alternative medicine use in breast cancer patients in Europe
    Molassiotis, A
    Scott, JA
    Kearney, N
    Pud, D
    Magri, M
    Selvekerova, S
    Bruyns, I
    Fernadez-Ortega, P
    Panteli, V
    Margulies, A
    Gudmundsdottir, G
    Milovics, L
    Ozden, G
    Platin, N
    Patiraki, E
    [J]. SUPPORTIVE CARE IN CANCER, 2006, 14 (03) : 260 - 267